Cargando…
Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
As global supply is still inadequate to address the worldwide requirements for HPV vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine. In this randomized, double-blind, placebo-controlled, phase 2 trial, healthy 9–45-year-old Chinese females in three age cohorts (...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294733/ https://www.ncbi.nlm.nih.gov/pubmed/37249310 http://dx.doi.org/10.1080/21645515.2023.2209001 |